Advertisement

Addition of Pembrolizumab to Trastuzumab and Chemotherapy in Previously Untreated Patients With Advanced HER2-Positive Gastric Adenocarcinoma
Posted: 03/17/2022 | By: Matthew Stenger

Question 1 of 5

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer supported:

Choose 1

A
The regular approval of pembrolizumab plus trastuzumab
B
The regular approval of pembrolizumab
C
The accelerated approval of pembrolizumab plus chemotherapy
D
None of the above

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage